Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG ZWINGENBERG, Germany, July 23, 2025 – The Supervisory Board of BRAIN Biotech AG is once again fully staffed: Dr. Ursula La Cognata has been appointed as a new member of the 6-person Supervisory Board by the Darmstadt District Court with effect from July 11, 2025 until [ … ]

BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25 BRAINBiocatalysts experienced modest organic growth in the first half of the year BRAINBioIncubator with high basis for comparison in the previous year Strong liquidity maintained at €14.9 million ZWINGENBERG, Germany, May 28, 2025 – BRAIN Biotech AG, a leading provider of [ … ]

BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center Breatec B.V. is now fully owned by BRAIN Biotech AG following a minority buyout New and enlarged production site will open close to Eindhoven, NL Expanded competence center for enzyme-based baking applications Z [ … ]

Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling  [ … ]

BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAINBiocatalysts organic growth at 11 % in Q1 Quantitative guidance looking at strong growth and solid adjusted EBITDA margin for BRAINBiocatalysts in FY 2024/25 Strong cash position maintained at € 17.8 million while reducing [ … ]

Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative Development of BioXtractor V2 pilot by BRAIN and PX Group and production of first BioGold nuggets from a local waste stream Extension of cooperation between the two companies as part of the PX Urban Mining Initiative PX Urban Mining Initiativ [ … ]

Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects Group cash and cash equivalents improved to € 27.2 million Successfully closed two milestone transactions with Royalty Pharma and Akribion Therapeutics Management sees a strong start to the new financial year Updated mid-term tar [ … ]